A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
Novartis
M.D. Anderson Cancer Center
Akeso
University of Wisconsin, Madison
University Health Network, Toronto
Institut du Cancer de Montpellier - Val d'Aurelle
Akeso
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Pfizer
Sun Yat-sen University
Toray Industries, Inc
UNICANCER
Emory University
Helsinki University Central Hospital
National Cancer Institute (NCI)
Academic and Community Cancer Research United
Cancer Institute and Hospital, Chinese Academy of Medical Sciences